RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...
invivodata Captures Symptom Relief Data in Endometriosis Trial
Neurocrine Biosciences Demonstrates Rapid and Significant Pain
Reduction with Elagolix
PITTSBURGH, Sept. 25 /PRNewswire/ -- invivodata inc., the industry
leader in electronic patient reported outcomes (ePRO) solutions and
services for global clinical research, today announced that its DiaryP...
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
- Focalin XR demonstrated better symptom
control versus Concerta from 30 minutes to six hours post-dose in primary and secondary endpoints
- Only Focalin XR provided onset of effect as early as 30 minutes post-dose
- Additional analysis suggests Focalin XR provides comparable efficacy to ...
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing
time to symptom
resolution data from a study (study 302) of Shire plc's
(LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA(TM), will be
presented today at Digestive Disease Week (DDW). Study 302 (further
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
Additional Digestive Disease Week data highlight effects of AMITIZA in patients with IBS-C
SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that
treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief
of overall symptoms of Irritable Bow...
New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
announced findings from a new data analysis that was conducted to examine
treatment differences with DAYTRANA(TM) (methylphenidate transdermal
system) between ...
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Interim Results From Open-Label Follow-up Include Longer-term Safety Findings
BOSTON, Oct. 26 /PRNewswire/ -- Adults with Attention Deficit
Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R)
methylphenidate HCl Extended-release Tablets showed signif...
New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients Symptom
resolution results based on stringent endpoint of clinical remission is more clinically relevant, beneficial to patients
PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- An analysis of data to
be presented tomorrow at the American College of Gastroenterology (ACG)
Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
- Data Presented at the 132nd Annual Meeting of the American Neurological Association in Washington, D.C. -
ATLANTA, Oct. 8 /PRNewswire/ -- UCB, Inc. presented results from two
Phase III pivotal trials and one open-label extension trial of rotigotine
transdermal system for the...
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline
(NYSE: GSK ) today announced new results from a large study that demonstrate
combination treatment with AVODART (dutasteride) and the alpha blocker
tamsulosin provides significantly greater urinary symptom
New Study Demonstrates that Lubiprostone May Improve Symptom Relief
Rates in Adults with Irritable Bowel Syndrome with Constipation
WASHINGTON, May 21, 2007 /PRNewswire/ -- A new study
demonstrated that the active ingredient in Amitiza (lubiprostone),
given 8 mcg twice a day, may improve symptom
relief rates in adults
with irritable bowel syndrome with constipation (IBS-C). These
results were presented as a late-breaker at Dig...
Daytrana (methylphenidate transdermal system) Provides Significant
Effectiveness in ADHD Symptom Relief in Both Boys and Girls
SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc
announced today that DAYTRANA(TM) (methylphenidate transdermal
system), its Attention Deficit Hyperactivity Disorder (ADHD) patch,
had significant efficacy in reducing the symptoms of ADHD in both
male and female children aged 6 to 12 yea...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
...ical outcomes in schizophrenia."
The approval is based on four acute symptom
control studies and a longer-term maintenance study that compared INVEGA(R)... placebo in the longer-term maintenance study.
The most recent acute symptom
control study was a multi-center, randomized, placebo-controlled, double-bl...
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
...eatment" for patients suffering a stroke was expanded to eight hours within symptom
onset, rather than the standard three-hour window required by the FDA-appro...al Hospital -- Harvard Medical School, presentation beyond eight hours of symptom
onset has traditionally been the single most important factor in excluding ...
July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
... recovery. There's some controversy on their effectiveness. Mayo Clinic doctors say there may be benefit if the drugs are given within the 72 hours of symptom
For most people, symptoms begin to improve within a few weeks. Complete recovery may take three to six months or even longer in sever...
Dry Mouth Linked to Prescription and Over the Counter Drugs
...to be a very serious condition, as it relates to the promotion of tooth decay;
Approximately 68 percent say constant thirst is the most common symptom
communicated by patients; 44 percent say patients have difficulty eating, swallowing or speaking;
More than 92 percent report that patients a...
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
...inate at night thereby
disturbing sleep significantly) is a common condition, with prevalence
increasing markedly with age. It is often the presenting symptom
in men with
benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients.
There is currently no adequate treatment for nocturia and it ...
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
...dose and for the 6 g/night dose. Sodium oxybate-treated patients also reported highly statistically significant improvement in fatigue, another common symptom
The most common adverse events (greater than or equal to five percent and at least twice the rate of placebo) were nausea, dizzi...
Neurocrine Biosciences Presents Elagolix Data
...oladex(R) (goserelin acetate) are highly effective in controlling symptoms of endometriosis, these products cause an initial, transient heightening in symptom
severity, as well as hot flashes throughout the course of therapy. Most importantly, because all GnRH agonists suppress estrogen to very low levels, l...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
"In the GO-RAISE trial, treatment with golimumab provided sustained symptom
relief to patients living with the chronic inflammatory disease, ankylosing...nnaire scores were also maintained through two years.
"The sustained symptom
relief demonstrated in these Phase 3 studies is encouraging," said Robert J...
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
... (baseline) period before undergoing the 12-week treatment period, followed by a two-week post-treatment period. Daily assessments of bowel habits and symptom
severity, and weekly global assessments were performed using an interactive voice response system. During the baseline period patients had to demonstr...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
..., P=0.002, FACT-L Lung Cancer Subscale; ZEAL: HR 0.61, P=0.004, Lung Cancer symptom
Scale). Overall survival in both studies showed a positive trend, although ...; OS: HR 1.01, 95.08% CI 0.89-1.16; P =0.830). Objective response rate and symptom
control were also similar for both treatments (ORR: both 12%; symptoms: pai...
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
...ts approval for ADHD in adults in 2008, VYVANSE has been an important treatment option for physicians treating adult patients seeking significant ADHD symptom
control during their busy day," said Jeffrey Jonas, Senior Vice President of Research & Development for the Specialty Pharmaceuticals business at ...
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
...c asthma. Results showed decreases in mean asthma symptom
scores without a change in lung function for both ...osinophils and expired nitric oxide (FeNo), asthma symptom
scores, required beta agonist use, and cortisol levels. The mean asthma symptom
score decreased significantly in both treatment gr...
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
...) is not approved for the treatment of patients with dementia-related psychosis.
Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom
complex, has been reported with the use of antipsychotic medications, including RISPERDAL(R) CONSTA(R). Clinical manifestations include muscle rigidit...
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
...-dose study, INTUNIV demonstrated significant ADHD symptom
improvement in patients with oppositional symptoms...s study presented today, INTUNIV also demonstrated symptom
improvement as measured by three different rating ... course of the study.
Significantly greater symptom
reductions were also seen on the Conduct Problem S...
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
...y marketed drugs for narcolepsy, according to Khayrallah. ADX-N05 has shown the potential to treat excessive daytime sleepiness as well the associated symptom
of cataplexy, an abrupt and temporary episode of weakness that can result in collapse. ADX-N05 also exhibited the potential to decrease DREM, the dire...
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
... in 2008 - 2009. It enrolled 405 subjects 18 years of age or older with acute uncomplicated influenza confirmed by positive rapid antigen test, whose symptom
duration was 36 hours or less. The primary analysis population consisted of patients with confirmed influenza A. Approximately 79 percent of subjects...
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
...in relief at 2 hours post-dose, using the standard IHS 4-point rating scale. Secondary efficacy endpoints for the trial include pain relief and other symptom
assessments at various time points. Safety evaluations will also be made throughout the clinical trial period. Alexza projects that data from the Ph...
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
...A submissions are based on the results of these studies.
About NEXIUM (R) (esomeprazole magnesium)
NEXIUM 20 mg is indicated to maintain symptom
resolution and healing of EE (controlled studies did not extend beyond 6 months), and for treatment of heartburn and other symptoms associated with GE...
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
...ther of 500 IR, with a placebo group. The endpoint
was the adjusted average symptom
score on nasal symptoms assessed during the
three last months of the year. ...f rescue medication was allowed throughout the period.
The adjusted average symptom
score has been improved by 20% in both treated
groups. In particular, the n...
Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
... or due to insurance coverage. The researchers measured the efficacy of the medications using several parameters, including the International Prostate symptom
Score (IPSS), peak flow rate (Qmax), post-void residual urine (PVR), voiding diary information, International Index of Erectile Function (IIEF), ejacu...
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
...tion and used by doctors to diagnose and classify ADHD in children and adolescents.
In both studies, Clonicel showed improvement across all three symptom
domains of ADHD; attention, hyperactivity, and impulsivity. Clonicel was well-tolerated and had a favorable safety profile, with mild adverse events ...
American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought
...for 24 weeks with daily asthma diaries, every 4-week spirometry, and asthma symptom
Participants were classified with respect to GER statu... outcomes including pulmonary function, airways reactivity, asthma control, symptom
scores, nocturnal awakenings, or quality of life. GER documented by pH prob...
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
-- New product, now available in pharmacies, will provide rapid symptom
relief for number one reason men visit a urologist --
CORONA, Calif.,...H symptoms compared with placebo, as measured by the International Prostate symptom
Score (IPSS). IPSS includes irritative (frequency, urgency, and nocturia),...
Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment
... "Many people who suffer from GERD do not get complete relief of symptoms with drug therapy. The LINX System is intriguing because it may provide both symptom
relief and correction of the physiologic defect ."
The LINX Reflux Management System is intended to restore the normal barrier function in ...
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
...overed by Eisai Co., Ltd. and licensed by Radius (excluding Japan) in 2006.
About Vasomotor Symptoms (Hot Flashes)
Hot flashes are a common symptom
during menopause, experienced by more than 75% of women during the menopause transition for a median duration of four years. These symptoms can disrup...
March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots
...h day-to-day activities, it's time to see a doctor. Overwhelming worry is a symptom
of generalized anxiety disorder (GAD). The March issue of Mayo Clinic Heal...cur on their own, independent of other health concerns. Or anxiety can be a symptom
of several health conditions, such as heart or lung disease, thyroid proble...
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
...many other small molecule therapies.
The antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate OBD, a symptom
complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallma...
Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
...n Aerovant therapy as compared to placebo. Secondary endpoints include pulmonary function, time to exacerbation, daily peak expiratory flow (PEF) and symptom
scores, immunoglobulin E (IgE) levels, and fractional concentration of expired nitric oxide (FeNO).
"Regulatory clearance and initiation of AeroT...